Larry Anderson Jr., M.D., Ph.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Hematology and Oncology. He treats plasma cell disorders that include multiple myeloma, Waldenström's macroglobulinemia, amyloidosis, and other gammopathies. He specializes in treating these diseases with bone marrow transplantation.

In 2000, Dr. Anderson earned both a medical degree from the University of Texas Medical School at Houston and a doctoral degree in immunology from MD Anderson Cancer Center and the UT Graduate School of Biomedical Sciences/Health Science Center at Houston.

He completed an internship and residency in internal medicine at the Mayo Clinic’s Graduate School of Medicine, followed by a fellowship in medical oncology at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center, where he later served as a research associate.

Certified by the American Board of Internal Medicine in both internal medicine and medical oncology, he joined the UT Southwestern faculty in 2008.

Dr. Anderson’s research interests include cancer immunology, immunotherapy, multiple myeloma, and stem cell transplantation. His research has been funded by the American Cancer Society, National Institutes of Health, American Society of Clinical Oncology, and the Multiple Myeloma Research Foundation.

Dr. Anderson is a member of the American Society of Hematology and the Texas Medical Association, and he is a Diplomate of both the American Board of Internal Medicine (ABIM) and the ABIM Subspecialty Board of Medical Oncology.

He was named a Texas Monthly Super Doctor in 2018.


Medical School
UT Health Science Center McGovern Medical School (2000)
Mayo Clinic (2003), Internal Medicine
Fred Hutchinson Cancer Research Center (2006), Medical Oncology

Research Interest

  • Cancer immunology
  • CAR T-Cells
  • Immunotherapy
  • MAGE-C1 (CT-7)
  • Multiple Myeloma
  • Stem Cell Transplantation


Featured Publications LegendFeatured Publications

The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
Bergstrom CP, Dahiya S, Chen W, Zhang CC, Zhu H, Yan J, Madanat Y, Patel P, Vusirkala M, Ramakrishnan P, Rizvi S, Chung S, Awan F, Anderson LD, Collins R, Kansagra A, Leuk Res 2020 Nov 100 106480
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S, Lancet 2020 11 396 10262 1563-1573
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.
Germans SK, Kulak O, Koduru P, Oliver D, Gagan J, Patel P, Anderson LD, Fuda FS, Chen W, Jaso JM, Am J Clin Pathol 2020 11 154 6 816-827
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Dimopoulos M, Weisel K, Moreau P, Anderson LD, White D, San-Miguel J, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Casal E, Srinivasan S, Yu X, Nguyen TV, Biyukov T, Peluso T, Richardson P, Leukemia 2020 Sep
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Lunning M, Usmani SZ, Anderson LD, Chhabra S, Girnius S, Shustik C, Stuart R, Lee Y, Salman Z, Liu E, Valent J, Hematol Oncol 2020 Aug 38 3 353-362

Honors & Awards

  • Elected as a Fellow of the American College of Physicians
    FACP (2021)
  • Texas Super Doctor
  • Leukemia & Lymphoma Society North Texas Man of the Year
  • Texas Super Doctor Rising Star
  • ACS Institutional Research Grant
    Research Grant (2010)
  • ASCO Young Investigator Award
    Research Grant (2006)
  • K12 Career Development Award
    Research Grant (2006)
  • Multiple Myeloma Research Foundation Fellow Award
    Research Grant (2006)

Professional Associations/Affiliations

  • American Society of Clinical Oncology (2017)
  • American Society for Transplantation and Cellular Therapy (2014)
  • American College of Physicians (2013)
  • American Society of Hematology